J.P. Morgan Healthcare Conference: Industry Mood and FDA Concerns
The recent J.P. Morgan Healthcare Conference in San Francisco provided a snapshot of the biopharmaceutical industry’s current outlook. While expectations were for a slightly improved atmosphere compared to the previous year, some uncertainty remained.
Richard Pazdur and the Food and Drug Administration
Former Director of the Food and Drug administration’s (FDA) Center for Drug Evaluation and Research (CDER), Richard Pazdur, recently retired in December 2025 after a period leading the agency. Reports indicate he has expressed concerns regarding the FDA’s current state. Pazdur’s tenure at the FDA spanned decades, and he was a key figure in the approval of numerous cancer therapies.
The J.P. Morgan conference served as a platform for industry experts to discuss trends and challenges, with the FDA’s performance and future direction being a prominent topic of conversation.
